91大神

91大神 Children's Health | 听

Skip to Content on 91大神.org
# #

Meet Our Team

Learn more about our physician researchers, clinicians and scientists.

Find a Researcher
Group of providers.

Partner With Us

Join forces with our world-class research teams. Whether in academia, industry, or health care, let鈥檚 advance children鈥檚 health together.

Learn How
Partnerships

Study With Us

Our research fellows directly impact the work we do. See our education opportunities and join us.

Apply Now
Group of providers

Join Our Team

Shape the future of pediatric medicine through groundbreaking research. Explore our research opportunities.

View Positions
Find a Researcher

Russell Taylor Sundby, MD

Physician
Provider Profile

91大神 Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803

Biography

R. Taylor Sundby, MD is board-certified pediatric hematologist oncologist and an Assistant Research Physician in the National Cancer Institutes' (NCI) Pediatric Oncology Brach (POB). Dr. Sundby received his BS at Haverford College before completing his medical training at the Vanderbilt University School of Medicine. At Vanderbilt, he completed a Medical Scholar Fellowship studying the effect of obesity on genetic heterogeneity in triple negative breast cancer. He pursued pediatrics residency at the University of California San Francisco as a member of the Clinical and Translational Science Pathway, investigating how vastly different malignant phenotypes and accumulated mutations arise across cancers stemming from common driver mutations. Dr. Sundby completed his Pediatric Hematology and Oncology Fellowship training program at the NCI-POB and Johns Hopkins University. His current clinical and research interests are in rare tumors and cancer predisposition syndromes with a focus on cancer prevention and early interception in neurofibromatosis through non-invasive cancer biomarker discovery, validation, and clinical application. He is a Francis S. Collins Scholar and previous recipient of the NextGen Award.

Fellowship

  • Pediatric Hematology-Oncology - Johns Hopkins University School of Medicine, 2020
  • Pediatric Hematology-Oncology - National Institutes of Health, 2020

Residency

  • Pediatrics - University of California, San Francisco, 2017

Education

  • MD - Vanderbilt University School of Medicine, 2014

Board Certifications

  • American Board of Pediatrics

  • Bioinformatics
  • Cancer Predispositions
  • Cfdna
  • Epigenetics
  • Genomics
  • Liquid Biopsy
  • Neurofibromatosis Type 1 (Nf1)
  • Rare Tumors
  • Sarcoma

  • A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder Cancer; JHEP Reports; (2026).

  • Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series; Neuro-Oncology Advances; (2026).

  • New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis; Cancers; (2026).

  • Rare cancers research: current state of knowledge and emerging opportunities for prevention and interception; JNCI: Journal of the National Cancer Institute; (2026).

  • SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST); Clinical Cancer Research; (2026).

  • Brain Metastasis in Pediatric Patients with Osteosarcoma; Current Oncology; (2024).

  • Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics; Unknown Source; (2024).

  • Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Clinical Cancer Research; (2024).

  • Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials; Clinical Trials; (2024).

  • A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Clinical Cancer Research; (2023).

  • Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.; JAMA dermatology; (2023).

  • Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA; Cancer Discovery; (2023).

  • MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors; Clinical Cancer Research; (2023).

  • Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Clinical Cancer Research; (2023).

  • Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients; npj Precision Oncology; (2023).

  • Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study; PLOS Medicine; (2021).

  • Liquid biopsies in pediatric oncology: opportunities and obstacles; Current Opinion in Pediatrics; (2021).

  • OC005: Ultrasound bioeffects: Quantification of cellular damage in animal fetal liver after use of Doppler pulse to measure ductus venosus; Ultrasound in Obstetrics and Gynecology; (2008).

  • Transduction of Human CD34+ Cells with Recombinant TAT-NF-YA Protein Enhances Their Ex Vivo Expansion and Repopulating Potential in NOD/SCID Mice; Blood; (2008).